TY - JOUR
T1 - New low-flux mixed matrix membranes that offer superior removal of protein-bound toxins from human plasma
AU - Pavlenko, Denys
AU - Van Geffen, Esmée
AU - Van Steenbergen, Mies J.
AU - Glorieux, Griet
AU - Vanholder, Raymond
AU - Gerritsen, Karin G F
AU - Stamatialis, Dimitrios
PY - 2016/10/5
Y1 - 2016/10/5
N2 - Hemodialysis is a widely available and well-established treatment for patients with End Stage Renal Disease (ESRD). However, although life-sustaining, patient mortality rates are very high. Several recent studies corroborated the link between dialysis patients' outcomes and elevated levels of protein-bound uremic toxins (PBUT) that are poorly removed by conventional hemodialysis. Therefore, new treatments are needed to improve their removal. Recently, our group showed that the combination of dialysis and adsorption on one membrane, the mixed matrix membrane (MMM), can effectively remove those toxins from human plasma. However, these first MMMs were rather large in diameter and their mass transport characteristics needed improvement before application in the clinical setting. Therefore, in this study we developed a new generation of MMMs that have a smaller diameter and optimized characteristics offering superior ability in removing the PBUT indoxyl sulfate (IS) and p-cresyl sulfate (pCS) in comparison to first generation MMMs (30 and 125% respectively), as well as, a commercial dialysis membrane (more than 100% better removal).
AB - Hemodialysis is a widely available and well-established treatment for patients with End Stage Renal Disease (ESRD). However, although life-sustaining, patient mortality rates are very high. Several recent studies corroborated the link between dialysis patients' outcomes and elevated levels of protein-bound uremic toxins (PBUT) that are poorly removed by conventional hemodialysis. Therefore, new treatments are needed to improve their removal. Recently, our group showed that the combination of dialysis and adsorption on one membrane, the mixed matrix membrane (MMM), can effectively remove those toxins from human plasma. However, these first MMMs were rather large in diameter and their mass transport characteristics needed improvement before application in the clinical setting. Therefore, in this study we developed a new generation of MMMs that have a smaller diameter and optimized characteristics offering superior ability in removing the PBUT indoxyl sulfate (IS) and p-cresyl sulfate (pCS) in comparison to first generation MMMs (30 and 125% respectively), as well as, a commercial dialysis membrane (more than 100% better removal).
UR - http://www.scopus.com/inward/record.url?scp=84990922491&partnerID=8YFLogxK
U2 - 10.1038/srep34429
DO - 10.1038/srep34429
M3 - Article
C2 - 27703258
SN - 2045-2322
VL - 6
JO - Scientific Reports
JF - Scientific Reports
M1 - 34429
ER -